Exenatide
Exenatide
The first GLP-1 receptor agonist approved (Byetta), derived from Gila monster venom. Available as twice-daily or once-weekly (Bydureon) formulation.
Typical Cost
$600-900/month (brand)
Status
Research
Peptide Profile
Exenatide
Mechanism of Action
Activates GLP-1 receptors from exendin-4, a peptide found in Gila monster venom. Stimulates insulin secretion, suppresses glucagon, reduces appetite.
Common Dosages
subcutaneous
5-10mcg
2x daily · Ongoing
subcutaneous (Bydureon)
2mg
Weekly · Ongoing
Benefits
Established safety profile
Moderate weight loss 3-5%
Good glycemic control
Twice daily or weekly options
Side Effects
Nausea
Vomiting
Injection site reactions
Less weight loss than newer GLP-1s
Key Research
Exenatide diabetes and weight
Demonstrated glycemic improvements and modest weight loss in type 2 diabetes
Regulatory Status
FDA-approved (Byetta twice daily, Bydureon weekly). Older GLP-1 with extensive safety data.
Contraindications
- ⚠Medullary thyroid carcinoma history
- ⚠Severe GI disease
- ⚠Pregnancy/breastfeeding
GLP-1 users on exenatide benefit from SeraVia formulations for enhanced metabolic and digestive support.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.